Skip to main content
S&P 5007,711.06+1.88%DOW53,293.19+2.91%NASDAQ25,904.76+2.10%BTC$80,617.00+3.72%ETH$2,430.56+5.69%GOLD$4,076.60+3.46%OIL$88.12-8.29%
Smart Investors Daily
SID Premium
Bioventus Inc. logo

NASDAQ · BVS

Bioventus Inc.

Healthcare · Medical - Devices

$10.95

Up+$0.78 (+7.13%)

Updated Nov 4, 2026, 5:49 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
495.93M
P/E ratio
63.41
Dividend yield
0.00%
52-week range
$6.47 – $15.89
Volume
2.45M
Avg. volume
310.75K

Price performance · BVS

BVS price history

1M range · 0 trading sessions · Daily adjusted prices

BVS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest BVS news

The latest Smart Investors Daily articles mentioning BVS.

Stock researchCompany · Overview

BVS research

Overview

Company profile and research snapshot.

Company profile

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.83
Implied upside
—
Analysts
—
BVS recent ratings
DateFirmRatingTarget
Nov 3, 2026Canaccord GenuityBuy—
Aug 17, 2026Canaccord GenuityBuy—
Aug 17, 2026Cantor FitzgeraldOverweight—
Jun 30, 2026Barrington ResearchOutperform—
Jun 16, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2026 after the market closes on Monday, November 2, 2026. The Company’s management will host a conference call at 4:30 p.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By